Tract Therapeutics


Tract Therapeutics is developing an adaptive regulatory T cell transfer platform as an alternative to transplant immunosuppressants and to treat autoimmune disorders.


Treg Adoptive T Cell Transfer-The immunosuppressants that transplant recipients take to prevent graft rejection can cause life threatening side effects. Regulatory T cells have previously been shown to suppress self-immune responses. The Tract platform uses a patient’s own regulatory T cells to suppress the graft rejection immune response after transplantation. White blood cells are harvested from the patient prior to transplantation and the regulatory T cells are isolated using MACS purification and expanded by co-culture with cytokines. The expanded regulatory T cells are then infused into the patient post-transplant. The platform is expandable to various types of autoimmune disorders including Crohn’s and Hepatitis.


A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T Cells In Living Donor Kidney Transplants
Mathew, JM; et al. Scientific Reports. 2018 May 9; 8(1): 7428

Cell Therapy in Kidney Transplantation; Focus on Regulatory T Cells.
Zwang, NA; Leventhal, JR. Journal of American Society of Nephrology. 2017 Jul; 28(7):1960-1972.


Immune Cell Selection, Expansion and Use

Development Stage


Phase II: Kidney Transplant

Phase I: Hepatitis, Crohn’s

Preclinical: Liver Transplant

Innovation Opportunity

  • Immunotherapy


Tract may be interested in academic or industry collaborations to expand the disease indications of its platform.

Contact Information

Claim Your Page
Is this your organization? Submit your contact information below.

Leave a Reply

Your email address will not be published. Required fields are marked *